Qyuns Therapeutics has entered exclusive global licensing agreement with Roche for long-acting bispecific antibody (BsAb) QX031N targeting TSLP and IL-33 pathways in chronic obstructive pulmonary disease (COPD) and asthma through a potential USD 1.07 billion deal, including a USD 75 million upfront payment. The pre-clinical candidate represents a first-in-class mechanism simultaneously inhibiting alarmin proteins involved in airway inflammation and remodelling, with potential best-in-disease profile for severe respiratory conditions refractory to current biologics, including IL-5- and IgE-targeted therapies.

The deal validates Qyuns' proprietary antibody engineering platform enabling extended half-life and improved tissue penetration. Meanwhile, Roche gains a strategic asset complementing its respiratory portfolio with a novel mechanism targeting upstream cytokines in the type 2 inflammation pathway, with potential applications in eosinophilic asthma and COPD exacerbation prevention.

PharmCube's NextBiopharm® database shows that Qyuns' pipeline includes one approved product and three Phase III candidates across dermatology, rheumatology and gastroenterology indications, with QX031N being the most advanced respiratory asset. Click here to request a free trial for NextBiopharm®.